VDAC1 and acute respiratory distress syndrome: Therefore, we concluded that (+)3C‐20 targeting VDAC1 in PBMCs from sepsis‐associated ALI patients, inhibiting mtDNA release to reduce inflammation, promises to be a potential application of ALI in future clinical research.